Last reviewed · How we verify

D064 and Placebo of D702, QD

Chong Kun Dang Pharmaceutical · Phase 3 active Small molecule

D064 and Placebo of D702, QD is a Small molecule drug developed by Chong Kun Dang Pharmaceutical. It is currently in Phase 3 development. Also known as: D064 Monotherapy.

Unfortunately, no information is available on the mechanism of action of D064.

At a glance

Generic nameD064 and Placebo of D702, QD
Also known asD064 Monotherapy
SponsorChong Kun Dang Pharmaceutical
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Further research is needed to understand the exact mechanism of action of D064.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about D064 and Placebo of D702, QD

What is D064 and Placebo of D702, QD?

D064 and Placebo of D702, QD is a Small molecule drug developed by Chong Kun Dang Pharmaceutical.

How does D064 and Placebo of D702, QD work?

Unfortunately, no information is available on the mechanism of action of D064.

Who makes D064 and Placebo of D702, QD?

D064 and Placebo of D702, QD is developed by Chong Kun Dang Pharmaceutical (see full Chong Kun Dang Pharmaceutical pipeline at /company/chong-kun-dang-pharmaceutical).

Is D064 and Placebo of D702, QD also known as anything else?

D064 and Placebo of D702, QD is also known as D064 Monotherapy.

What development phase is D064 and Placebo of D702, QD in?

D064 and Placebo of D702, QD is in Phase 3.

Related